10,501 Drugs in Pipeline, Oncology Dominates
Summary
The Patented Medicine Prices Review Board published its 2026 Meds Pipeline Monitor, reporting 10,501 new medicines in the clinical development pipeline as of August 2025, with 200 medicines in pre-registration stages. Oncology drugs comprised 40% of the pipeline across all development phases, maintaining dominance over infectious disease (second) and central nervous system disease (third) treatments. The report also identified five medicines under priority review by Health Canada and noted that 11 of 43 previously featured medicines have since received market authorization.
About this source
GovPing monitors PMPRB for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 6 changes logged to date.
What changed
The PMPRB released its annual Meds Pipeline Monitor, a surveillance publication tracking novel medicines in Phase III clinical trials or pre-registration that may seek Canadian market authorization. The report documents 10,501 total drugs in the pipeline as of August 2025, with 200 in pre-registration. Cancer medicines continued to represent 40% of all medicines across development phases. Orphan medicines made up 23% of Phase III trials and 24% of pre-registration medicines.
Pharmaceutical companies and investors with drugs in late-stage oncology development should note that cancer therapeutics will continue to dominate Health Canada's priority review queue. The report provides no new compliance obligations but serves as forward-looking intelligence on the competitive landscape likely entering the Canadian market in coming years.
Archived snapshot
Apr 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PMPRB report reviews new drugs that may enter the Canadian market in the near future
From: Patented Medicine Prices Review Board Canada
News release
PMPRB report reviews new drugs that may enter the Canadian market in the near future
April 27, 2026 — Ottawa, ON — Patented Medicine Prices Review Board
The latest edition of Meds Pipeline Monitor, from the Patented Medicine Prices Review Board, features a selection of new medicines undergoing clinical evaluation or in pre-registration that may gain market authorization in Canada in the future. There were 10,501 drugs in the pipeline as of August 2025.
Oncology represented 40% of medicines in all phases of clinical trials. Treatments for infectious diseases and central nervous system diseases held the second and third largest share of the pipeline.
The Meds Pipeline Monitor focuses on novel medicines undergoing Phase III clinical trials or in pre-registration with the US Food and Drug Administration (FDA). It also includes information on other drugs in Phase II that share the same mechanism of action or indication.
This edition of the report also highlights five new medicines currently under priority review by Health Canada.
Quick facts
- As of August 2025, the pipeline contained 10,501 new medicines across all stages of clinical development. The later stages of the pipeline had 200 medicines in pre-registration.
- Cancer medicines continued to dominate the therapeutic mix in 2025, representing 40% of medicines across all stages of development.
- Of the 43 medicines which had been featured in the last MPM, 11 have since received market authorization. 26 were retained on this year’s list as they continued to satisfy the selection criteria. Six were removed as their clinical trials were discontinued or they no longer met the selection criteria.
- Orphan medicines in the later stages of the pipeline made up 23% of medicines in Phase III clinical trials and 24% in pre-registration.
- Five new medicines under priority review by Health Canada are featured in the Spotlight on Canada section of this report.
Related products
Contacts
PMPRB Media Relations
PMPRB.MediaCentre-CentreMedias.CEPMB@pmprb-cepmb.gc.ca
Follow us on X @PMPRB_CEPMB and on LinkedIn.
Search for related information by keyword: Health and Safety | Patented Medicine Prices Review Board Canada | Canada | Drug labelling, pricing and health claim compliance | general public | media | news releases
Page details
2026-04-27
Related changes
Get daily alerts for PMPRB
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from PMPRB.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when PMPRB publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.